0001193125-26-211929
SEC filingDefinium Therapeutics reported Q1 2026 net loss of $77.1 million with R&D expenses rising to $41.5 million amid Phase 3 trial progress for DT120 ODT, and $373.4 million cash runway into 2028.
Definium Therapeutics reported significantly widened losses in Q1 2026, with net loss expanding to $77.1 million from $23.3 million year-over-year, driven primarily by escalated R&D spending of $41.5 million (up $18.1 million). This increase stemmed from $15.2 million more in DT120 ODT program expenses tied to advancing multiple Phase 3 trials, plus $3.2 million in personnel costs for expanded capabilities. G&A expenses nearly doubled to $17.7 million, fueled by $3.9 million in stock-based compensation, personnel, commercial readiness, and legal costs, signaling investments in scaling operations ahead of potential approvals. A $20.0 million unfavorable change in fair value of 2022 USD Financing Warrants further pressured the bottom line. Despite cash burn, the company maintained a robust $373.4 million in cash, cash equivalents, and investments (down from $411.6 million at year-end), providing runway into 2028 based on current plans. CEO Rob Barrow highlighted momentum with enrollment complete in Emerge (MDD, topline late 2Q 2026), Voyage (GAD, early 3Q 2026), and Panorama (GAD, late 3Q 2026, now targeting 200 participants), plus site activation for Ascend (MDD) and PTSD expansion via Haven study in 2027. These catalysts underscore the high-risk, high-reward profile as Definium advances DT120 ODT, a proprietary LSD formulation, toward regulatory milestones in psychiatry.